

Memphasys Continues European Commercial Roll-out with A\$350,000 Felix™ Agreement in Poland

Highlights

- **Approximately A\$350,000 (€212,000) minimum contracted value over the two-year commercial term**
- **TK Biotech Sp. z o.o. appointed exclusive commercialisation partner for Felix™ in Poland, subject to minimum purchase and performance obligations**
- **Poland becomes the third “European” market in which Felix™ has secured commercial sales or a commercialisation agreement since CE Mark approval, following Italy and the United Kingdom**
- **An initial three-month evaluation and market-introduction period provides a defined pathway to recurring revenue, with contracted quarterly purchase commitments commencing immediately afterwards**
- **The opportunity originated from inbound interest from TK Biotech and was progressed and finalised following meetings with Memphasys at ESHRE 2026 in London**

Memphasys Limited (ASX: MEM) (“Memphasys” or “the Company”) is pleased to announce it has entered into an exclusive commercialisation agreement with TK Biotech Sp. z o.o. (“TK Biotech”) for the sale and commercialisation of the Felix™ System in Poland.

The agreement represents a further step in the Company’s European commercial roll-out following CE Mark approval, with Felix™ now securing commercial agreements &/or sales in Italy, the United Kingdom and Poland. The opportunity arose from an inbound approach by TK Biotech and terms were finalised at the recent ESHRE Conference in London.

Poland’s IVF sector is expanding following the introduction of the Polish Government’s publicly funded IVF program in June 2024. As at 31 May 2026, the program was operating through 58 fertility clinics, had qualified more than 51,000 couples and had resulted in 29,806 clinical pregnancies and 15,000 births¹.

The increased accessibility and public funding of IVF treatment provide a supportive market environment for reproductive technologies that can improve patient clinical outcomes and clinical workflow efficiency.

¹ Polish Ministry of Health, “Program wsparcia in vitro”, program results as at 31 May 2026.

Agreement Structure

The agreement comprises an initial three-month evaluation period followed by a two-year commercial term. Minimum purchases over the commercial term have a total contracted value of approximately €212,000, equivalent to approximately A\$350,000

TK Biotech will place an initial evaluation order to support product training, clinic demonstrations and early market introduction. Subject to completion of the evaluation period, contracted quarterly purchase commitments will commence immediately thereafter and increase materially in the second agreement year.

Based on the current implementation timetable, the initial evaluation order is expected to be invoiced during the September 2026 quarter, with the first minimum quarterly purchase order expected in the December 2026 quarter. Revenue will be recognised as products are supplied and invoiced, with cash receipts subject to the agreed payment terms.

The appointment is exclusive to Poland while TK Biotech satisfies the agreed minimum purchase commitments and its material commercial, regulatory and market-development obligations. The agreement also includes performance incentives intended to support sales above the minimum contracted commitment.

TK Biotech will be responsible for satisfying applicable Polish importer, distributor and local supply-chain requirements. During the evaluation period, the parties will undertake product training, clinic engagement, demonstrations and market-development activities in preparation for recurring quarterly orders.

About TK Biotech

TK Biotech is a Warsaw-based distributor of laboratory equipment, diagnostic products and reagents for research centres, diagnostic laboratories and IVF clinics. Established in 2001, the company operates across IVF, diagnostics, life sciences, veterinary medicine, biotechnology and pharmaceuticals.

Its team includes specialists in biology, molecular biology and biotechnology who provide scientific advice, product support and assistance in selecting laboratory solutions. TK Biotech also maintains technical-service capability across major Polish cities.

TK Biotech has a dedicated IVF business and an established assisted-reproduction portfolio that includes products from international fertility and laboratory-technology companies. Its existing clinic relationships, scientific capability and technical-service network provide an established platform for the commercial introduction of Felix™ across Poland.

Commercial Model

The Poland agreement reflects Memphisys' in-country commercial partner model, under which the Company works alongside an experienced local distributor to support selling Felix, product education, clinical positioning, market adoption and then recurring cartridge sales.

TK Biotech will be responsible for developing relationships with IVF clinics, embryologists, fertility specialists and key opinion leaders throughout Poland, while providing product demonstrations, customer onboarding, training and first-line customer support.

Memphasys will provide product training, technical support, approved marketing materials and direct participation in selected clinic meetings, seminars, conferences and educational activities. Memphasys will continue to work with TK Biotech to finalise Felix business plans including IVF customer profiling, segmentation and targeting to drive recurring revenues beyond the minimum order requirements.

A/Prof Hassan Bakos, Director of Clinical Partnerships and Growth at Memphasys, commented:

“Poland is an important addition to our growing European commercial footprint and provides a clear pathway from evaluation to recurring quarterly orders. This opportunity came directly to Memphasys and was advanced rapidly through detailed discussions with TK Biotech, including meetings at ESHRE in London. TK Biotech has an established IVF presence and the technical capability to support clinics as Felix™ is introduced across the Polish market. We remain focused on converting the strong interest generated across Europe into contracted commercial partnerships and revenue.”

Anna Maria Pawlak, Sales Director IVF of TK Biotech added:

“The Polish IVF market presents a significant commercial opportunity as treatment volumes continue to grow. Following our evaluation of Felix™, we believe it provides IVF laboratories with an innovative sperm preparation technology that complements our existing portfolio and addresses an important clinical need. We are excited to partner with Memphasys and look forward to driving the commercial introduction of Felix™ throughout Poland.”

Outlook

Poland is Memphasys' second European Union commercialisation agreement and the third “European” market in which Felix™ has secured commercial sales or an agreement.

In anticipation of the additional demand arising from current late-stage contract negotiations and the strong sales pipeline secured during ESHRE in July, a major international conference for reproductive medicine, the Company has appointed a Director of Commercial Operations – Europe. He is highly experienced in the IVF arena and is expected to commence his role in mid-September 2026. The Director's role is to drive the European sales process, support partner onboarding, clinic conversion, support client key account management and help, over time, build the European team to support the growing client and partner base.

Memphasys also continues to progress discussions with additional prospective partners and IVF groups beyond Europe following its participation with Felix™ at ESHRE 2026. The Company's near-term focus is on converting these opportunities into initial orders, completed evaluations and recurring commercial purchases.

This announcement has been authorised for release by the Board of Memphasys Limited.

Ends

For further information, please contact:

Colin Jacoby

Chapter One Advisors

T: +61 433 112 936

E: cjacoby@chapteroneadvisors.com.au

About Memphasys

Memphasys Limited (ASX: MEM) is an Australian-based reproductive biotechnology company commercialising the Felix™ System, a patented bio separation technology that isolates the most viable sperm cells for human assisted reproduction.

By combining electrophoresis and size-exclusion membranes, Felix™ delivers a fast, gentle and standardised sperm selection process that enhances sperm quality and reduces laboratory time. The system replaces traditional centrifugation, which can cause cellular stress and DNA damage, offering clinicians a superior, repeatable alternative.

Memphasys' commercial strategy is focused on building contracted and recurring sales through direct and distribution-led channels, scaling production to support commercial growth and establishing Felix™ as a new global standard in sperm preparation for assisted reproductive technology procedures.

Website: www.memphasys.com

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Memphasys' current expectations, estimates and projections about the industry in which Memphasys operates, and its beliefs and assumptions.

Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties and are not guarantees of future performance. Memphasys cautions shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Memphasys only as of the date of this release.